FATE · Fate Therapeutics Inc
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.49M | $6.65M | $13.63M | $63.53M | $96.3M | $55.85M | $31.43M | $10.68M | $4.74M | $4.11M | $4.4M | $2.43M | — | $971K | $2.67M | $1.17M | — | — | — | |
| $100.35M | $107.83M | $135M | $172.6M | $320.45M | $215.52M | $125.62M | $87.77M | $56.02M | $34.36M | $26.45M | $19.86M | $16.44M | $12.01M | $12M | $9.86M | — | — | — | |
| $39.73M | $46.52M | $74.17M | $81.45M | $84.23M | $57.32M | $33.9M | $23.64M | $15.81M | $11.87M | $9.91M | $10.35M | $8.47M | $6.64M | $4.23M | $4.61M | — | — | — | |
| $11.99M | $12.9M | $18.96M | $18.28M | $13.76M | $5.85M | $3.09M | $2.19M | $1.2M | $971K | $881K | $687K | $496K | $571K | $590K | $672K | — | — | — | |
| — | $1.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $140.08M | $154.35M | $223.91M | $254.04M | $404.69M | $272.84M | $159.52M | $111.41M | $71.83M | $46.23M | $36.37M | $30.21M | $24.9M | $18.65M | $16.23M | $14.46M | — | — | — | |
| -$133.59M | -$147.7M | -$210.28M | -$190.51M | -$308.39M | -$216.99M | -$128.09M | -$100.73M | -$67.09M | -$42.13M | -$31.96M | -$27.78M | -$24.9M | -$17.68M | -$13.56M | -$13.29M | — | — | — | |
| — | -2222.45% | -1542.63% | -299.86% | -320.23% | -388.56% | -407.47% | -943.14% | -1415.44% | -1025.94% | -726.1% | -1142.82% | — | -1820.29% | -507.75% | -1136.15% | — | — | — | |
| -$121.6M | -$134.8M | -$191.31M | -$172.23M | -$294.63M | -$211.14M | -$125M | -$98.53M | -$65.89M | -$41.15M | -$31.08M | -$27.1M | -$24.41M | -$17.1M | -$12.97M | -$12.62M | — | — | — | |
| — | — | — | — | — | $0 | $0 | $1.75M | $1.7M | $1.27M | $1.64M | $2.22M | $549K | $796K | $487K | $127K | — | — | — | |
| $8.22M | $11.05M | $17.29M | $17.19M | $5.84M | $1.31M | $2.4M | $4.33M | $2.19M | $559K | $138K | $10K | $2000 | $6000 | $1000 | $2000 | — | — | — | |
| $7.59M | $11.39M | $24.01M | $29.58M | $26.67M | $4.84M | -$45.3M | $2.58M | $494K | -$827K | -$1.5M | -$2.21M | -$979K | -$3.22M | -$682K | -$134K | — | — | — | |
| — | $2000 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| -$126M | -$136.32M | -$186.26M | -$160.93M | -$281.72M | -$212.15M | -$173.39M | -$98.15M | -$66.6M | -$42.95M | -$33.46M | -$29.99M | -$25.88M | -$20.89M | -$14.24M | -$13.43M | -$16.22M | -$13.33M | -$7.17M | |
| — | -2051.08% | -1366.46% | -253.3% | -292.55% | -379.89% | -551.59% | -919% | -1405.02% | -1046.08% | -760.15% | -1233.73% | — | -2151.8% | -533.3% | -1147.61% | — | — | — | |
| USD/shares | -$1.05 | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 | -$2.10 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$1.05 | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 | -$2.10 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 5.9M | 1.09M | 830.96K | — | — | — |
| shares | — | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M | 68.19M | 56.2M | 41.98M | 31.75M | 25.48M | 20.45M | 5.9M | 1.09M | 830.96K | — | — | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 318 similar-size Biotechnology companies (of 537 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| Commercial Option Exercise | $10,000,000 | $13,000,000 |
| Associated With Collaboration Services | — | $1,300,000 |